Introduction
Gastric cancer (GC) is one of the most common malignancies in the digestive tract (Huang et al., 2012) . Despite rapid advances in diagnosis and treatment, GC is the second leading cause of cancer death worldwide (Ferlay et al., 2010) . The prognosis of GC patients with advanced disease remains poor and combination chemotherapy remains the main treatment options (Wagner et al., 2010) . Recently, it has been reported that doublet and triplet regimens, especially taxane-based regimens,
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Xiu-Feng Hu, Jun Yao, She-Gan Gao, Xin-Shuai Wang, Xiu-Qing Peng, YanTong Yang, Xiao-Shan Feng* (Merikallio et al., 2012) . High Nrf2 expression predicts chemoresistance and tumor progression in patients with advanced-stage non-small-cell lung cancer (Yang et al., 2011) . Nrf2 knockdown inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer (Ma et al., 2012) . Nrf2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer (Shibata et al., 2011) . These studies suggest that Nrf2 may be involved in the progression and drug resistance in tumor biology. However, it remains unclear whether Nrf2 participates in the tumor progression and drug resistance in GC.
In this study, we examined the expression of Nrf2 protein in GC specimens and assessed the correlations between Nrf2 expression and clinicopathological characteristics. In addition, we investigated the relationship between expression of Nrf2 and drug resistance to chemotherapeutic agents in GC patients treated with chemotherapy and GC cell lines.
Materials and Methods
Patients and samples
This study was approved by the Ethics Committee All tumors were histologically diagnosed as gastric adenocarcinoma by two independent pathologists and were subjected to immunohistochemistry. None of these patients had received treatment such as chemotherapy and/ or radiotherapy before operation. The median follow-up period was 36 months (range 3.0-108 months).
For chemoresistance investigation, 142 GC specimens were obtained via biopsy under endoscopy from gastric cancer patients who underwent chemotherapy and were subjected to immunohistochemistry.
Chemotherapeutic regimens and treatment responses
Seventy-three of 142 patients received combination chemotherapy of docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DFP) before surgery. The remaining 69 patients were treated with combination chemotherapy of S-1 plus cisplatin (SP). In DFP therapy, treatment included docetaxel (60 mg/m 2 on day 1), 5-FU (350 mg/m 2 /day continuously intravenous administration on days 1-5), and cisplatin (10 mg/m 2 /day on days 1-5), which was repeated twice every 28 days before evaluating treatment responses using computed tomography and gastric endoscopy. In SP therapy, the treatment consisted of S-1 (80 mg/m 2 /day on days 1-21) and cisplatin (60 mg/m 2 on day 8), which was repeated twice every 35 days before evaluating therapeutic responses.
Tumor response was assessed by computed tomography after two cycles of either treatment according to the Response Evaluation Criteria in Solid Tumors criteria (Therasse et al., 2000) . Complete response (CR) was defined as the absence of all evidence of cancer for more than 4 weeks. Partial response (PR) was defined as more than a 50% reduction in the sum of the products of the perpendicular diameters of all lesions without any evidence of new regions or progression of any lesions. Stable disease (SD) was defined as less than a 50% reduction or less than a 25% increase in the sum of the products of the perpendicular diameters of all lesions, without any evidence of new lesions. Progressive disease (PD) was defined as more than a 25% increase in more than one region or the presence of new regions.
Immunohistochemical (IHC) analysis
Nrf2 expression was evaluated by IHC staining according to a previously described method (Jala et al., 2013) . Tissue slides were deparaffinized in xylene and then rehydrated through graded ethanol. Tissue slides were incubated overnight with Nrf2 antibody (dilution 1:1,000, Santa Cruz) at 4°C. Sites of antibody binding were visualized with the ABC peroxidase detection system (Vector Laboratories). Finally, sections were counterstained with 0.1% hematoxylin. The percentage of cancer cells with positive staining was evaluated.
IHC staining was evaluated by two independent pathologists, who were blinded to the clinical data. In the present study, the scoring pattern for Nrf2 staining was as follows: score 0, negative staining for all cells; score 1+, weakly positive for cytosolic staining in <10% of cells; score 2+, moderate to strong positive staining covering between 10 to 50% of cells and score 3+, strongly positive staining including >50% cells. For statistical purposes,IHC scores were grouped into two groups, low expression (0 and 1+) and high expression/overexpresion (2+ and 3+).
Cell lines and cultures
Human gastric epithelial cells (HGEC) and human GC cell lines including HGC-27, AGS, MKN28, and MGC803, were obtained from the American Type Culture Collection and kept in our laboratory. All cell lines were maintained in Dulbecco's Modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (Hyclone) in 5% CO 2 at 37°C.
RNA extraction and quantitative RT-PCR
Total cellular RNA was extracted from each cell line with Trizol Reagent (Invitrogen) according to the manufacturer's protocol. The primer sequences for quantitative RT-PCR (qPCR) amplification were as follows, Nrf2: 5'-TCCAGTCAG AAACCAGTGGAT-3'(forward) and 5'-GAATGTCTGCGCCAAAAGCTG-3'(reverse), GAPDH was used as an internal control: 5'-ACAACTTTGGTATCGTGGAAGG-3' (forward) and 5'-GCCATCACGCCACAGTTTC-3' (reverse). The emission intensity of SYBR Green was detected in a LightCycler (Roche Diagnostics). The Nrf2 expression was adjusted by GAPDH in each sample.
Nrf2 small interfering RNA
Cells were cultured up to 80% confluence and transfected with 5 nmol/L of Nrf2 small interfering RNA (siNrf2) or negative control scrambled RNA (Life Technologies) with the siPORT Amine Agent (Life Technologies) as per the manufacturer's protocol. After transfection, cells were cultured for 48h and samples were collected at 24 and 48 h and were analyzed by qRT-PCR, Western blotting and MTT assay.
Western blot
GC tissues or adherent cells were washed with PBS and lysed in RIPA buffer (Qiagen), and the supernatant was collected. Equal amounts of cell extracts were fractionated by SDS-PAGE (Bio-Rad Laboratories) and transferred onto membranes (Millipore). After blockade with milk, membranes were incubated overnight at 4°C with primary antibodies and with secondary antibodies for 1 hour at room temperature. The following antibodies were used in this study: anti-GAPDH (1:1,000; Abcam) and anti-Nrf2 (1:1,000; Abcam). Enhanced chemiluminscence substrate was used to detect the signal.
Cell viability assay and chemotherapeutic agents
The MTT assay was used to assess cell viability. Cells were seeded onto 96-well plates at a concentration of 
5×10
3 per well and incubated overnight under the standard culture conditions; they were exposed to each of docetaxel, cisplatin, and 5-FU (Shanghai Zhongxi Biopharm Ltd., China) at various concentrations. After 10 μl of MTT solution was added to each well, the plates were incubated for 4 h at 37°C. The absorbance was measured at 570 nm, with 655 nm as the reference wavelength. All experiments were performed in triplicates. Docetaxel was dissolved in DMSO. 5-FU and cisplatin were dissolved in RPMI 1640.
Statistical analysis
Statistical analysis was performed with SPSS16.0. The relationship between Nrf2 expression and various clinicopathological parameters was assessed by the Chisquare test. Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method and log-rank test. All parameters that were found to be significant on univariate analysis by the Cox proportional hazard model entered into multivariate survival analysis. P<0.05 were considered significant.
Results
Nrf2 expression and its association with clinicopathological features in GC
Immunohistochemistry was performed in 186 GC samples. As shown in Figure 1A , Nrf2 protein was mainly located in the cytoplasm. Nrf2 was significantly overexpressed (2-3 score) in 55.9% (104/186) GC cases. In contrast, none of adjacent noncancerous tissues showed Nrf2 overexpression. Further, using Western blot in GC, we confirmed the higher expression of Nrf2 in GC samples than adjacent noncancerous tissues ( Figure 1B) .
The correlation between Nrf2 expression and clinicopathological characteristics was shown in Table 1 . Nrf2 overexpression was positively correlated with tumor size (P=0.013), lymph node invasion (P=0.009), venous invasion (P=0.016) and TNM stage (P=0.005). In addition, Nrf2 expression correlated significantly with correlated significantly with poor OS and DFS ( Figure 1C, D) .
Prognostic significance of Nrf2 expression in GC
Cox's proportional hazard model was further used to examine the various correlations between various parameters and survival of patients (Table 2 ). Univariate analysis showed that TNM stage, lymph node invasion and Nrf2 expression correlated with OS. However, multivariate analysis identified Nrf2 expression as the only significantly independent prognostic factor for OS of GC patients (HR=3.9). Associations between various clinicopathological parameters and DFS were also analyzed by Cox's proportional hazard model (Table  2 ). Univariate analysis showed that TNM stage, vessel invasion, lymph node invasion, and Nrf2 expression significantly correlated with DFS. Multivariate analysis identified TNM stage and Nrf2 expression as independent prognostic predictors for DFS of GC patients (HR=3.3 and 4.3, respectively).
Nrf2 expression and response to chemotherapy
We also investigated the association between clinical response to chemotherapy and Nrf2 expression (Table 3) . Among the 73 specimens treated with DFP, 51 (69.9%) were diagnosed as overexpression and 22 (30.1%) as low expression for Nrf2 by immunohistochemistry. The response rate to DFP therapy in 51 patients with Nrf2 overexpression was 31.4% (16/51), while the response rate to DFP therapy in 22 patients with low Nrf2 expression was 77.3% (17/22). There was a significant negative correlation between clinical response to DFP therapy and Nrf2 expression (p=0.014). Among the 69 specimens treated with SP therapy, 44 (63.8%) were diagnosed as overexpression and 25 (36.2%) as low expression for Nrf2 by immunohistochemistry. The response rate to SP therapy in 44 patients with high Nrf2 expression was 56.8% (25/44) and in 25 patients with low Nrf2 expression was 40% (10/25). There was no relationship between clinical response to SP therapy and Nrf2 expression (p=0.392).
Knockdown of Nrf2 reduced the resistance to 5-FU
First, we detected the Nrf2 protein expression in HGEC and four human GC cell lines including HGC-27, AGS, MKN28, and MGC803. We found that the protein expression of Nrf2 was higher in each of the four GC cell lines than that in the control (HGEC) cells, and the highest expression was observed in MGC803, as indicated by Western blot (Figure 2A) .
Next, we chose the MGC803 cells, with the highest Nrf2 expression, for the gene silencing experiment. qRT-PCR and Western blot analysis indicated that Nrf2 siRNA reduced the expression of Nrf2 at mRNA and protein levels, compared with that of control siRNA ( Figure 2B , C). We examined chemosensitivity to docetaxel, cisplatin, and 5-FU by the MTT assay using Nrf2 siRNA-treated MGC803 cells for 48 h and control siRNA-treated cells. The MTT assay showed that chemosensitivity to 5-FU was significantly increased in MGC803 cells by Nrf2 siRNA (Figure 2D, IC50 ; 21 vs. 2.9 μg/ml), while resistance to cisplatin and docetaxel remained unchanged.
Discussion
Nrf2 shows dual roles in cancer, but more emerging data support its role as a protooncogene (Shelton et al., 2013) . In the present study, we found Nrf2 was significantly overexpressed in the GC samples and GC cell lines. And we examined the clinical significance of Nrf2 overexpression in human GC. As a result, Nrf2 overexpression was an independent prognostic factor for OS and DFS in human GC. Furthermore, we also found enhanced Nrf2 expression was associated with 5-FU resistance in GC patients and cell lines. Our data also showed that downregulation of Nrf2 improved the sensitivity of chemotherapy in GC cell lines. Taken together, this study indicates that Nrf2 will be a promising marker for predicting prognosis and chemoresistance of GC. Intriguingly, multiple human cancers frequently exhibit overexpresion levels of Nrf2. Overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents and downregulation of the Nrf2 rendered cancer cells more susceptible to these drugs in human lung carcinoma, breast adenocarcinoma and neuroblastoma cells (Wang et al., 2008) . Activation of Nrf2 confers radioresistance in non-small-cell lung cancer cells . Inhibition of Nrf2 in DU-145 cells enhanced sensitivity to chemotherapeutic drugs and radiation-induced cell death, and greatly suppressed in vitro and in vivo tumor growth of DU-145 prostate cancer cells . Cancer cells acquire malignant properties by hijacking the Keap1-Nrf2 system (Yoichiro et al., 2012) . Indeed, the prognosis of Nrf2-positve patients with lung cancer is significantly poor (Solis et al., 2010; Inoue et al., 2012) . Consistently, our data show that enhanced Nrf2 expression predicts in GC. Furthermore, Nrf2 confers 5-FU resistance in GC patients and cell lines. These data indicate that dysfunction of Nrf2 can be both a cause of GC and chemotherapy resistance in GC. Nevertheless, detailed mechanisms remain unclear and merit further investigation.
The present novel finding in may provide therapeutic target for the sensitivity of GC and could be applied to treat chemotherapy resistance in GC patients. Future investigations are needed to further support the pathogenic function of Nrf2 in GC prognosis and drug resistance. These investigations may help with the development of personalized treatment for patients who have abnormal levels of Nrf2.
